Summary:
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis
Criteria:
18 Years or older
Must be clincially diagnosed with Ulcerative Colitis for 90 prior to Day 1
Qualified Participants May Receive:
Reimbursment for time and travel
No cost study medication
No cost lab examination
Treatment possibility for Ulcerative Colitis